Radiotherapy plus durvalumab in locally advanced NSCLC: the DOLPHIN study

被引：0
|
作者：
Trommer, Maike [1 ,2 ,3 ,4 ]
机构：
[1] Med Fak, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Klin & Poliklin Radioonkol Cyberknife & Strahlenth, Cologne, Germany
[2] Univ Klinikum Koln, Cologne, Germany
[3] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Dept Radiat Oncol, Melbourne, Australia
[4] Univ Klinikum Koln, Ctr Mol Med Cologne CMMC, Cologne, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2024年 / 200卷 / 07期
关键词：
D O I：
10.1007/s00066-024-02231-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646 / 648
页数：3
相关论文
共 50 条
  • [41] INTENSITY MODULATED RADIOTHERAPY OR PROTON BEAM THERAPY FOR LOCALLY ADVANCED NSCLC
    Komaki, Ritsuko
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S437 - S438
  • [42] Erlotinib plus radiotherapy in patients with locally advanced rectal cancer
    Smorenburg, CH
    Van Triest, B
    Van der Sijp, JRM
    Van Groeningen, CJ
    Giaccone, G
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 40 - 40
  • [43] Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
    Tachihara, Motoko
    Tsujino, Kayoko
    Ishihara, Takeaki
    Hayashi, Hidetoshi
    Sato, Yuki
    Kurata, Takayasu
    Sugawara, Shunichi
    Okamoto, Isamu
    Teraoka, Shunsuke
    Azuma, Koichi
    Daga, Haruko
    Yamaguchi, Masafumi
    Kodaira, Takeshi
    Satouchi, Miyako
    Shimokawa, Mototsugu
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 9167 - 9173
  • [44] Safety and activity of durvalumab plus tremelimumab in immunotherapy (IMT)-retreated advanced NSCLC patients.
    Garon, Edward B.
    Spira, Alexander I.
    Goldberg, Sarah B.
    Chaft, Jamie E.
    Papadimitrakopoulou, Vassiliki
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Camidge, D. Ross
    Powderly, John D.
    Wozniak, Antoinette J.
    Felip, Enriqueta
    Gao, Guozhi
    Englert, Judson M.
    Awad, Mark M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).
    Keane, Fergus
    Schoenfeld, Joshua David
    Crowley, Fionnuala
    O'Connor, Catherine Anne
    White, Charlie
    Schwartz, Carly
    Brenner, Robin
    Larsen, Mary
    Park, Wungki
    Varghese, Anna M.
    Yu, Kenneth H.
    Li, Jia
    Zervoudakis, Alice
    Goldberg, Zoe
    Chou, Joanne F.
    Vardhana, Santosha
    Reyngold, Marsha
    Crane, Christopher H.
    Tuli, Richard
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 725 - 725
  • [46] Clinical Activity, Patient-Reported Outcomes, and Safety With Durvalumab After Chemoradiation in Locally Advanced, Unresectable NSCLC: Pacific Study
    Hui, Rina
    Antonia, Scott J.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 145 - 145
  • [47] A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)
    Spreafico, A.
    Sultanem, K.
    Chen, B.
    Bratman, S. V.
    Ringash, J.
    Louie, A. V.
    McNiven, A.
    Whelan, K.
    Hilton, J.
    Yoo, J.
    Machiels, J-P.
    Licitra, L. F.
    Oosting, S.
    Waldron, J. N.
    Siu, L. L.
    Parulekar, W. R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 399 - 399
  • [48] Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC
    Kawajiri, Kazuki
    Shinno, Yuki
    Shirasawa, Masayuki
    Sato, Daiki
    Takeyasu, Yuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [49] A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma
    Patel, Shetal A.
    Gibson, Michael K.
    Deal, Allison
    Sheth, Siddharth
    Heiling, Hilary
    Johnson, Steven M.
    Douglas, Kathe
    Flores, Melissa
    Blumberg, Jeffrey
    Lumley, Catherine
    Yarbrough, Wendell G.
    Shen, Colette
    Chera, Bhishamjit S.
    Bauman, Jessica R.
    Hackman, Trevor
    Weiss, Jared
    [J]. CANCER, 2023, 129 (21) : 3381 - 3389
  • [50] Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
    Farastuk Bozorgmehr
    Inn Chung
    Petros Christopoulos
    Johannes Krisam
    Marc A. Schneider
    Lena Brückner
    Daniel Wilhelm Mueller
    Michael Thomas
    Stefan Rieken
    [J]. BMC Cancer, 20
12345